Show me Q1 2025 earnings call Q&A session for biogen

### Analysts Q&A Summary:

1) Brian Abrahams – RBC Capital Markets
– The question: Congrats on the recent Leukembi approval in Europe. Can you talk about what the rollout strategy could look like there and your sense of what the reimbursement process and amenability could be?
– The response: The rollout in Europe will take some time because a first-in-class product like Lykimbi adds to the healthcare budget rather than cannibalizing it. The European Medicines Agency’s examination of efficacy, safety, and economic benefits could aid the reimbursement process. However, the launch will still require market-by-market negotiation.

2) Evan Seigerman – BMO Capital Markets
– The question: Touch on Lekembi’s subcutaneous formulation for at-home administration and its potential impact on accelerating sales in the U.S.
– The response: Subcutaneous formulation will simplify maintenance therapy, extending treatment life. It may appeal to patients in rural areas from the start, depending on accessibility to infusion centers, reducing the physician’s workload and improving patient and caregiver convenience.

3) Salveen Richter – Goldman Sachs
– The question: Your thoughts on LAKEMBY uptake and growth with subcutaneous maintenance dosing in the second half and FujiGuy’s in vitro diagnostic.
– The response: The diagnostic could aid in early diagnosis, allowing treatment at an earlier stage in the disease. There’s optimism that these diagnostics will shorten the time to proper Alzheimer’s diagnosis and beginning treatment before neuronal damage becomes extensive.

4) Tim Anderson – Bank of America
– The question: How is the market parsing out between Biogen’s LAKEMBY and Lilly’s Kusuma regarding commercial positioning around finite dosing?
– The response: It depends on the physician’s choice, influenced by age and patient’s location (urban vs. rural). Focus is on expanding the market, not merely market share, as treatment can significantly benefit a larger number of eligible patients.

5) Chris Schott – JPMorgan
– The question: Business development thoughts—size, scope, and market volatility effect on opportunities for Biogen.
– The response: There’s a shift in the market with healthcare investors under pressure to liquidize. Valuation discourse may open discussions more easily. Collaborations, even in early-stage opportunities, are being pursued, seeing potential in the current market climate.

6) Michael Yee – Jefferies
– The question: About early AHEAD-three 45 study—major points about differentiation compared to competitors and confidence about the study’s readout.
– The response: AHEAD study focuses on the full spectrum of Alzheimer’s disease, using advanced evaluation methods to gauge the best deployment of therapy at various amyloid stages. Results could only be interpreted fully by 2028, but earlier data insights are possible without projecting interim analysis.

7) Terence Flynn – Morgan Stanley
– The question: Comments on FDA’s stance and potential changes to rare disease treatment progressions, specifically surrogate endpoints.
– The response: No major changes noticed with FDA interactions; encouraging comments from the new commissioner about using novel processes for approval of rare diseases, suggesting potential regulatory leniency and innovation.

8) Jeff Meacham – Citibank
– The question: Thoughts on manufacturing capacity in the U.S. and if there’s an opportunity to partner for excess capacity.
– The response: Recent expansions in Europe provide CDMO opportunities, and in the U.S., the RTP facility already engages in third-party manufacturing, indicating a robust position to leverage manufacturing competency further.